Goldman Sachs
MCRB icon

Goldman Sachs’s Seres Therapeutics MCRB Stock Holding History

Goldman Sachs’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,500
Closed -$172K – 6433
2022
Q2 		$172K Hold
2,500
– – ﹤0.01% 5695
2022
Q1 		$356K Buy
+2,500
New +$385K ﹤0.01% 5557
2016
Q2 		– Sell
-1,750
Closed -$930K – 7155
2016
Q1 		$930K Hold
1,750
– – ﹤0.01% 4133
2015
Q4 		$1.23M Buy
+1,750
New +$1.15M ﹤0.01% 4096

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Goldman Sachs's MCRB Position: Q2 2026 in Review

Goldman Sachs opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 15,229 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #6311 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in MCRB as recently as Q4 2025.

Goldman Sachs first reported a position in MCRB in Q3 2015 and has held it in 41 quarters since. The position peaked at $18.7M in Q1 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Goldman Sachs held 15,229 shares of Seres Therapeutics worth $120K as of Q2 2026.
  • Seres Therapeutics was a new Goldman Sachs position in Q2 2026.
  • Seres Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6311 holding.
  • Goldman Sachs first reported a position in Seres Therapeutics in Q3 2015 and has held it in 41 quarters since.
  • Goldman Sachs's Seres Therapeutics position peaked at $18.7M in Q1 2021.
  • 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.